SCHEMBL29471220

SCHEMBL29471220

Cc1cc2c(Br)cccc2[nH]c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.53
DAO P14920 5/20 0.51
DDO Q99489 4/20 0.51
ATAD2 Q6PL18 1/20 0.47
CYP1A2 P05177 3/20 0.46
TNKS2 Q9H2K2 2/20 0.46
CYP2C19 P33261 1/20 0.46
HRH4 Q9H3N8 1/20 0.43
FLT3 P36888 1/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
PARP1 P09874 2/20 0.41
MEN1 O00255 1/20 0.41
TNKS O95271 1/20 0.41
LMNA P02545 1/20 0.41
GPR3 P46089 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
KMT2A Q03164 1/20 0.41
PARP15 Q460N3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26551030 1.00 BRD4 (0.53) BRD4DAODDOATAD2CYP1A2
SCHEMBL30667289 0.83 DAO (0.71) BRD4DAODDOATAD2CYP1A2
SCHEMBL16627652 0.83 KDM4E (0.45) DAODDOCYP1A2TNKS2HRH4
SCHEMBL20247282 0.83 DAO (0.71) BRD4DAODDOATAD2CYP1A2
SCHEMBL30480858 0.79 DAO (0.54) DAODDOCYP1A2TNKS2HRH4
SCHEMBL20940200 0.79 DAO (0.65) BRD4DAODDOATAD2CYP1A2
SCHEMBL12970533 0.79 DAO (0.65) BRD4DAODDOATAD2CYP1A2
SCHEMBL15690473 0.79 DAO (0.65) DAODDOCYP1A2TNKS2HRH4
SCHEMBL15690324 0.78 GRIN2D (0.51) DAODDOCYP1A2HRH4FLT3
SCHEMBL31098173 0.77 GAA (0.50) CYP1A2TNKS2CYP2C19HRH4FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4210683-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS Aurigene Oncology Limited (IN) 2023-07-19 EP disclosed
CN-116368128-A Heterocyclic compounds as CBP/EP300 bromodomain inhibitors 奥瑞基尼肿瘤有限公司 2023-06-30 CN disclosed
WO-2022053967-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2022-03-17 WO disclosed